New KRAS-Selective Inhibitor to Show Clinical Data
Adults with advanced solid tumors may soon see a new treatment option as clinical trial results are presented this November.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Should regulatory requirements for cancer drug clinical trials be relaxed to accelerate patient access?
Alterome Therapeutics will share Phase 1/1b clinical trial results for ALTA3263 in adults with advanced solid tumors on November 20, 2026. This San Diego-based company is testing the oral medication as a potential treatment for colorectal cancer and pancreatic ductal adenocarcinoma.
Why it matters
Current cancer treatments often struggle to target specific genetic mutations, making the development of drugs that inhibit KRAS mutations a critical area of focus. If effective, this therapy could offer a new targeted option for patients with advanced disease.
The upcoming presentation details results from a Phase 1/1b clinical trial of ALTA3263 in adult patients with advanced solid tumors, including colorectal and pancreatic cancers. These findings remain preliminary as researchers continue to evaluate the drug's safety and dosage.
The players
Alterome Therapeutics
A San Diego-based biotechnology company focused on developing targeted small-molecule inhibitors for cancer treatments.
David S. Hong
A medical researcher who will present findings from the ALTA3263 clinical trial.
The details
ALTA3263 functions as an orally available, KRAS-selective pan-mutant inhibitor. The drug is designed to inhibit oncogenic KRAS mutations by targeting the protein in both its active (ON) and inactive (OFF) states. The ongoing study utilizes a dose-escalation design to determine optimal therapeutic levels for patients.
Timeline
November 19, 2026: Preclinical data regarding ALTA3263 will be presented.
November 20, 2026: Clinical trial data for ALTA3263 will be presented.
Health Landscape
The development of KRAS-selective inhibitors represents a shift toward more precise, mutation-focused oncology care. This study follows the broader effort to overcome historical challenges in drugging the KRAS protein across its various functional states.
Patients with advanced solid tumors, particularly colorectal or pancreatic cancer, may monitor these clinical updates as indicators of potential future treatment paths. Any interest in clinical trial participation should be discussed with a primary oncologist to determine eligibility.
The takeaway
Targeting KRAS mutations is a fast-evolving field that seeks to provide more effective options for difficult-to-treat solid tumors. If you are managing advanced cancer, ask your physician if your specific tumor profile makes you a candidate for upcoming clinical trials involving targeted inhibitors.
Further reading
For more information on the latest breakthroughs in oncology research, visit Cancer.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should regulatory requirements for cancer drug clinical trials be relaxed to accelerate patient access?
